Aldehyde dehydrogenase (ALDH) is a candidate marker for lung cancer cells with stem cell-like properties. Immunohistochemical staining of a large panel of primary non-small cell lung cancer (NSCLC) samples for ALDH1A1, ALDH3A1, and CD133 revealed a significant correlation between ALDH1A1 (but not ALDH3A1 or CD133) expression and poor prognosis in patients including those with stage I and N0 disease. Flow cytometric analysis of a panel of lung cancer cell lines and patient tumors revealed that most NSCLCs contain a subpopulation of cells with elevated ALDH activity, and that this activity is associated with ALDH1A1 expression. Isolated ALDH þ lung cancer cells were observed to be highly tumorigenic and clonogenic as well as capable of 
Introduction
The cancer stem cell model suggests that in many cancers, tumor initiation and propagation is driven by a population of self-renewing tumor cells known as cancer stem cells (CSCs) or tumor propagating cells (TPCs; ref. 1) . CSCs/TPCs likely facilitate tumor cell heterogeneity, metastases, and therapeutic resistance, and are potentially driven by known developmental signaling programs providing opportunities for biomarkers and therapeutic targets (2) (3) (4) .
Recent evidence suggests that human lung cancers, like other tumors, and transgenic mouse models of lung cancer may also harbor CSC populations (5, 6) . Identification of human lung CSCs has been hampered by the lack of reliable normal lung epithelial stem cell markers (7) . One potential human CSC marker is the membrane antigen CD133 (Prominin) identified in subpopulations of cells in brain, colon and lung tumors (8) (9) (10) . However, conflicting results on the detection, abundance, and tumorigenicity of CD133 þ tumor cells, indicate the need for additional markers to identify lung CSCs (11) (12) (13) . The expression and activity of aldehyde dehydrogenases (ALDH) is another potential CSC marker (14, 15) . Aldehyde dehydrogenase enzymes are a family of intracellular enzymes that participate in cellular detoxification, differentiation, and drug resistance through the oxidation of cellular aldehydes (16) . Enzymatic ALDH activity is important for the preservation of undifferentiated hematopoietic stem cells, by interfering with the biosynthesis of endogenous retinoic acids, and rare ALDH þ acute myelogenous leukemia cells have an enriched capacity for engraftment in recipient NOD/SCID mice (17) (18) (19) 
Materials and Methods

Cell lines and tumor samples
Nearly all lung cancer cell lines used in this study were established by our laboratory or obtained from the American Type Culture Collection, and maintained in RPMI-1640 (Life Technologies Inc.) with 5% FBS (23, 24) . All of the cell lines have been DNA fingerprinted for provenance using the PowerPlex 1.2wkit (Promega) and confirmed to be the same as the DNA fingerprint library maintained by ATCC and the Minna/ Gazdar laboratory (the primary source of the lines), and confirmed to be free of mycoplasma by e-Myco kit (Boca Scientific). Lung tumor (LT) samples were collected from consenting patients after surgery and mechanically disassociated. A single cell suspension of tumor cells was confirmed by microscopy after 1 to 2 hours of incubation with 1 mg/mL of Collagenase I (Gibco) at 37 C and passage through a 70-mm filter. Early passage murine lung adenocarcinoma cells cultured in DMEM with 5% FBS, were derived from double transgenic CCSP-rtTA/tet-o-K-Ras G12D mice with an Ink4a/ ARF À/À background as reported previously (25) .
Tissue microarray preparation and IHC evaluation Archived, formalin-fixed, paraffin-embedded (FFPE) tissues from clinically annotated, surgically resected lung cancer specimens containing tumor and adjacent normal epithelium tissues were obtained from the Lung Cancer Specialized Program of Research Excellence (SPORE) Tissue Bank at MD Anderson Cancer Center used to construct NSCLC tissue microarray (TMA1) for immunohistochemical (IHC) stains and EGFR and KRAS mutations as described (26) . IHC staining for ALDH1A1 using monoclonal antibodies (1:100; Abcam), ALDH3A1 (1:200; Santa Cruz Biotechnology), and CD133 (1:50; Miltenyi Biotec) was performed on TMA samples and assigned an expression score as described (26, 27) . NSCLCs were dichotomized into high and low expression classes on the basis of ALDH1A1 and ALDH3A1 median expression scores, whereas tumors with detectable CD133 expression were scored CD133 þ .
Aldefluor assay and flow cytometry
The Aldefluor kit (Stem Cell Technologies) was used to profile and separate cells with high and low ALDH activity (14) . Cells were incubated in Aldefluor assay buffer containing the ALDH protein substrate BODIPY-aminoacetaldehyde (BAAA) for 45 minutes at 37 C. Cells that could catalyze BAAA to its fluorescent product BODIPY-aminoacetate (BAA) were considered ALDH þ . Sorting gates for FACS were drawn relative to cell baseline fluorescence, which was determined by the addition of the ALDH-specific inhibitor diethylaminobenzaldehyde (DEAB) during the incubation and DEAB-treated samples served as negative controls. Nonviable cells were identified by propidium iodide inclusion. Cells were sorted by a MoFlow (Cytomation) or BD Aria (BD Biosciences) and the purity of sorted cells was assayed after the sort was completed. In costaining experiments, cells were incubated with monoclonal anti-CD133-APC (Miltenyi Biotec), anti-EpCam-PE (BD Biosciences) or anti-Sca-1-PE (BD Pharmigen) antibodies in Aldefluor assay buffer for 20 minutes at 4 C. ALDH gating in patient tumor samples was performed on EpCam þ cells to exclude potential ALDH þ stromal cells ( Supplementary Fig. 1 ). Hoechst 33342 dye excluding, Side Population cells (SP), were identified and analyzed as described (28) . Cell-cycle analysis was performed on cells 72 hours after treatment with either DMSO or 25 mmol/L of DAPT. Briefly, cells were fixed in cold 70% EtOH and incubated at 37 C for 45 minutes in staining buffer containing 100 mg/mL of propidium iodide, 50 mg/mL of RNAse A, 0.05% Triton X-100, and PBS. Flow cytometric analyses were performed on a FACScan or FACSCalibur flow cytometer (BD Biosciences), and figures were produced using FlowJo software (Treestar).
Colony formation assays
For soft agar colony formation assays, cells were suspended in 0.33% SeaKem agar (FMC Bioproducts) in growth medium supplemented with 20% FBS and plated in quadruplicate over a layer of 0.5% agar base medium in 12-well plates; and after 2 to 3 weeks, colonies were stained with 0.05% crystal violet and counted. For liquid colony formation assays, limiting dilutions of tumor cells were placed on 6-well plates (9.5-cm 2 well area) in growth media (in the presence or absence of DAPT) and after a 2-week incubation, colonies were stained with 0.5% methylene blue and counted using Image J software (NIH).
In vivo tumor formation assays
Subcutaneous tumor growth was monitored for 8 weeks by caliper measurements of tumor volume (equal to the width Â length 2 Â p/6). Limiting dilutions of H358 cells expressing CMV promoter driven luciferase (H358-luc) were injected into the subcutaneous flank of 4 NOD/SCID mice per dilution. Bioluminescence Imaging (BLI) of H358-luc tumors was performed after subcutaneous injection of 450 mg/kg of D-luciferin substrate (Biosynth) in PBS into anesthetized mice, as described (29) . Images were taken for 5 minutes, starting 10 minutes after D-luciferin injection, with a CCD camera (Caliper Xenogen). Patient lung cancer cells were suspended in a 1:2 mixture of Matrigel and PBS after FACS and injected subcutaneously into the flank of NOD/SCID mice. Incidence of xenograft tumor formation was scored 10 weeks after injection and detected, palpable tumors were excised and presence of human EpCam þ confirmed by flow cytometry.
qRT-PCR analysis Total RNA was isolated from sorted cells using an RNeasy mini kit (Qaigen) and subjected to RT-PCR using an iScript cDNA synthesis kit (BioRad). Gene-specific TaqMan probes (Applied Biosystems) were used for quantitative analysis of mRNA transcript levels of GAPDH and Notch pathway genes in duplicate samples from sorted cells. The comparative C T method (Applied Biosystems) was used to calculate relative expression values. Expression of gene transcripts in ALDH þ cells were normalized to the bulk population of ALDH À cells.
Expression analysis in unsorted samples was normalized to a reference sample containing pooled RNA from normal human and tumor tissues (Stratagene).
shRNA stable expression in lung cancer lines A pLKO.1 lentiviral shRNA vector targeted against NOTCH3 was purchased from Open Biosystems (Source ID: TRCN0000020237). An shRNA vector directed against GFP was used as a negative control. Lentiviruses were made by transfection of 293T packaging cells with a 3-plasmid system. 293T cells were grown in DMEM containing 10% FBS and transiently transfected with shRNA vector together with pMD. G-VSVG and pCMV-DR8.91 plasmids using Fugene6 (Roche). After overnight incubation, medium from 293T cells was changed to medium of target cells. The viral supernatant was used for the transduction of lung cancer cells with 8 mg/mL of polybrene (Sigma-Aldrich). Stable shRNA expressing lung cancer cells were generated after 2 weeks of culture in puromycin.
Statistical methods
Kaplan-Meier survival analysis was performed and illustrated using GraphPad Prism 5 software and survival curve comparison analyses were performed using the log-rank (Mantel-Cox) test. The Chi-square test was utilized to test the distribution of clinical covariates in ALDH1A1, ALDH3A1, and CD133 expression categories. The Fisher's exact test was performed on the associations between protein expression and EGFR and KRAS mutation status. Multivariate analysis for survival was carried out using SPSS software. Simple linear regression analysis was performed to determine correlation among expression scores in TMA samples. ANOVA and Student's t tests were performed to test for significance differences in sorted cell growth in vivo and in vitro.
Results
ALDH1A1 but not ALDH3A1 or CD133 protein expression is correlated with poor clinical outcome in NSCLC patients
To test the hypothesis that NSCLCs with different CSC markers would have different clinical courses, we analyzed the IHC expression of ALDH1A1, ALDH3A1, and CD133 in more than 200 clinically annotated NSCLC samples (Fig. 1 Table 1 ). The effect of squamous histotype influenced the multivariate analysis causing ALDH1A1 expression to not be an independent predictor of survival. By contrast, tumor cell ALDH3A1 and CD133 expression was not associated with survival in all or in stage I, N0 patients (Fig. 1B, Supplementary Fig. 2 ). However, ALDH3A1 expression was associated with tumor stage and nodal involvement (Fig. 1B, Supplementary Table 1) . Likewise, tumor cell CD133 expression was associated with adenocarcinoma (AC) histotype, never-smoking status and EGFR mutations ( Fig. 1B and C, Supplementary Tables 1 and 2 ). Although there was a weak correlation of ALDH1A1 and ALDH3A1 expression, ALDH1A1 and CD133 expression were independent of each other ( Supplementary Fig. 3A ). We found examples of NSCLCs representing all possible combinations of IHC staining phenotypes for ALDH1A1, ALDH3A1, and CD133 indicating tumors can contain various subpopulations for these phenotypes ( Supplementary Fig. 3C ).
Detection of an ALDH þ subpopulation in primary human and murine lung tumors ALDH activity determine by the Aldefluor assay has identified CSCs in a variety of tumor types (14, 15, 18) NSCLC cell lines tested (comprising 0.1%-38% of the total cell population, and also observed by microscopy in Fig. 2C ) and in the epithelial component of all 11 NSCLC patient tumors tested (2%-30% of the total EpCam þ cell population; Fig. 2 Supplementary Fig. 4 ).
Enhanced tumorigenicity of ALDH þ lung cancer cells
CSCs exhibit a high capacity for tumorigenic growth as mouse xenografts (8) (9) (10) formation by bioluminescence NSCLC cells and found H358-luc ALDH þ cells to have a greater frequency of tumor formation, particularly at low numbers of injected cells, compared with ALDH À counterparts (Fig. 3C , Table 1 ).
Uncultured NSCLC tumor samples were also sorted for ALDH activity, injected into NOD/SCID mice, and scored for tumor formation after 10 weeks. Only mice injected with ALDH þ primary tumor cells had detectable tumors (Table 1) .
Analysis of ALDH in EpCam þ cells from the fresh primary
and xenograft tumors showed them to be similar (Fig. 3E) . Similarly, reanalysis of tumors derived from sorted H358 cells revealed ALDH þ tumors contained a proportion of ALDH þ cells similar to their unsorted parental H358 cells, whereas the much smaller tumors derived from ALDH À cells were found to possess a very small residual ALDH þ cell population (Fig. 3D ). These data suggest that isolated Fig. 4A and B) . In addition, ALDH þ lung cancer cells generated more colonies with a densely packed morphology, whereas colonies generated from ALDH À lung cancer cells, formed diffuse and abortive colonies (Fig. 4C ), similar to CSC "holoclones" and non-CSC "meroclones" reported in prostate cancer (32 Supplementary Fig. 5 ).
Reduction of Notch signaling inhibits self-renewal of ALDH þ lung cancer cells
We characterized potential stem cell signaling pathways important for lung CSC maintenance by using qRT-PCR and found elevated expression of NOTCH1, NOTCH2, and NOTCH3, and HES1, HEY1, and HEY2 in ALDH þ compared to ALDH À cells from the same NSCLC line indicating Notch pathway activity is enhanced in the ALDH þ subpopulation (Fig. 5A ).
Previous studies have indicated Notch signaling is involved in normal and tumor stem cell homeostasis (33) (34) (35) . To test whether Notch signaling was involved in maintenance of ALDH þ cells, we treated NSCLC cells with DAPT, a g-secretase inhibitor that blocks the cleavage and release of intracellular Notch, thus suppressing canonical Notch signaling. In NSCLC cells treated for 5 days with DAPT, we observed a reduction of HES1, HEY1, and HEY2 mRNA expression, a dose-dependent reduction in the number of ALDH þ tumor cells, and cell-cycle arrest (which was greater in ALDH þ compared to ALDH À cells; Fig. 5B-D, Supplementary Fig. 6 ; refs. 36, 37). Analysis of a panel of normal immortalized human bronchial epithelial cells (HBECs) and lung tumor cell lines for expression of Notch transcripts and ALDH, revealed elevated NOTCH3 expression had the greatest correlation with percentage of ALDH þ cells in NSCLC (Supplementary Fig. 7) . Notch3 signaling appears to be important in lung development and lung cancer proliferation (38) (39) (40) . To determine its functional importance, we stably expressed a NOTCH3 shRNA (or control shGFP vector) in H358 and H2009 cells and found decreased expression of NOTCH3 and downstream targets HEY1 and HEY2 but not HES1, decreased clonogenic capacity, and decreased ALDH þ numbers in shNOTCH3-expressing cells ( Fig. 6; ref. 40 ). Taken together, these findings indicate that Notch signaling is important for the maintenance of ALDH þ lung CSCs.
Discussion
In the current study, we have applied a promising new stem cell marker, ALDH activity, to identify and enrich for a subpopulation of lung cancer cells with many of the properties ascribed to CSCs (5). We confirmed the utility of ALDH as a means to enrich for lung CSCs, demonstrated the correlation of ALDH activity with ALDH1A1 expression and demonstrated the sensitivity of lung CSCs to perturbations of the Notch signaling pathway. We found NSCLCs to vary in their abundance of ALDH1A1-expressing tumor cells, and tumors enriched for ALDH1A1-expressing cells were associated with a reduced patient survival, consistent with the idea that these tumors are enriched in CSCs. We also compare the expression of 3 putative lung CSCs markers, ALDH1A1, ALDH3A1, and CD133, in a large sample of diverse NSCLCs and found that these markers identified different tumor subpopulations. While our work was in progress, Jiang et al. found ALDH expression to be associated with reduced survival in stage 1 NSCLCs and reported a high degree of overlap between CD133 and ALDH1 expression, suggesting that these proteins were identifying the same tumor cell populations (21) . Our analysis confirmed the association between tumor ALDH1A1 expression and impaired survival in stage I and N0 tumors, but found no association with ALDH3A1, or CD133, and no association between ALDH1A1 and CD133 expression. We also noted histotype association of these markers, specifically ALDH1A1 with squamous cell and CD133 with adenocarcinomas of the lung. Flow cytometric analysis of tumor cell lines and patient samples found that most NSCLCs possessed a readily detectable ALDH þ cell population. However, in contrast to the report by Jiang et al., we did not find a bimodal distribution of ALDH activity in lung cancer cell populations, where the ALDH þ cell population was conspicuously larger and brighter than their ALDH À cell counterparts (21) . This discrepancy is possibly due to the inclusion of cellular debris during the Jiang et al. analysis that confounds the detection and proper isolation of viable ALDH þ and ALDH À cells, which are of great importance for cell growth and tumor formation studies (30) .
To avoid this problem, we employed a gating strategy that excluded cell debris and nonviable cells from our assay. We found that most SCLCs are greatly enriched in both ALDH activity and CD133 expression; suggesting CSCs are relatively more abundant in SCLCs. Recently, elevated ALDH and CD133 expression was found to be controlled by the neuronal lineage factor ASCL1 and knockdown of this gene transcript lead to a reduction in SCLC ALDH activity and xenograft formation (41) . These observations suggest that ALDH is also associated with an important subpopulation in SCLC that requires further characterization.
In mice, Sca-1 has been described as a stem cell marker in a variety of murine tissues including normal lung, mammary gland, and prostate, as well as in lung cancers (6, 42, 43) . By analyzing adenocarcinoma cells from K-Ras-induced Ink4a/ ARF À/-mice, we discovered the ALDH þ cells to be enriched in Finally, we set out to characterize the molecular features associated with the ALDH þ cells, including targetable signaling pathways known to be involved in stem cell physiology. We found elevated expression of Notch signaling transcripts in isolated ALDH þ lung cancer cells. The Notch pathway is an important developmental pathway that regulates critical cell fate determination and stem cell maintenance (44) . In NSCLC, elevated Notch expression in mutant p53 NSCLCs is associated with diminished patient survival and Notch signaling is also implicated in tumor hypoxia, angiogenesis, and proliferation, making this pathway an appealing target for therapy (45) (46) (47) . Inhibition of Notch3 receptor signaling has been demonstrated to reduce NSCLC cell growth in vitro and shrink human NSCLC xenografts (38) (39) (40) 48) . Using a g-secretase inhibitor to suppress Notch signaling in lung cancer cells, we observed a significant reduction in ALDH þ tumor cells, whereas shRNA-mediated knockdown of NOTCH3 also resulted in the reduction of clonogenic ALDH þ cells. Taken together, our results, like those in colon, brain, and breast CSCs, indicate a role for Notch signaling in lung CSC maintenance and suggest lung CSCs are sensitive to Notch inhibition (34, 49, 50) . Further, molecular characterization of lung CSCs will likely yield additional information about lung CSC as well as additional targets for therapy.
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